Suggested remit: To appraise the clinical and cost effectiveness of zuranolone within its marketing authorisation for treating severe postnatal depression.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6431

Provisional Schedule

Committee meeting 06 August 2025
Expected publication 15 October 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol

Stakeholders

Companies sponsors Biogen (zuranolone)
Others Department of Health and Social Care
  NHS England
Patient carer groups Action on Postpartum Psychosis
  Association for Post Natal Illness
  Association of Mental Health Providers
  Bipolar UK
  C.A.L.M
  Child Bereavement UK
  Depression UK
  Maternal Mental Health Alliance
  Mental Health Foundation
  Mental Health Matters
  MIND
  National Childbirth Trust
  PANDAS
  PAPYRUS
  Race Equality Foundation
  Rethink
  Sands - Stillbirth and neonatal death charity
  SANE
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Matthew Trust
  WISH - A Voice for women's mental health
Professional groups British Association for Counselling and Psychotherapy
  British Association for Psychopharmacology
  British Association of Behavioural and Cognitive Psychotherapies
  British Association of Occupational Therapists and College of Occupational Therapists
  British Association of Social Workers
  British Geriatrics Society
  British Neuropsychiatry Association
  British Psychoanalytic Council
  British Psychological Society
  British Psychotherapy Foundation
  College of Mental Health Pharmacy
  Counsellors and Psychotherapists in Primary Care
  Health and Care Professions Council
  Mental Health Nurses Association
  Primary Care Mental Health Education
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians and Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Psychiatrists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine)
  Amneal Pharma Europe (duloxetine, paroxetine)
  Arristo Pharma (quetiapine)
  AstraZeneca (quetiapine)
  Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline and venlafaxine)
  Chiesi (venlafaxine)
  Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine)
  Creo Pharma (lofepramine and trazodone)
  Dexcel Pharma (venlafaxine)
  Dr Reddys Labs (duloxetine, fluoxetine and sertraline)
  Fontus Heath (quetiapine)
  GlaxoSmithKline (paroxetine)
  HBS Healthcare (duloxetine)
  Kyowa Kirin (phenelzine)
  Lilly UK (duloxetine and fluoxetine)
  Lundbeck (citalopram, escitalopram, vortioxetine)
  Lupin (sertraline)
  Marlborough (doxepin)
  Merck Sharp & Dohme (mirtazapine)
  Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine)
  Par Laboratories Europe (fluoxetine)
  Pfizer (reboxetine, sertraline and venlafaxine)
  Rivopharm (citalopram, trazodone)
  Sandoz (citalopram, paroxetine and quetiapine)
  Servier (agomelatine)
  SilverCloud (Space from Depression)
  Sun Pharmaceuticals (sertraline and venlafaxine)
  Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine)
  Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine)
  Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Council for Wales
  Care Quality Commission
  Department of Health - Northern Ireland
  Gofal
  Hafal
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  MIND Cymru
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Social Care Institute for Excellence
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Campbell Collaboration Social Welfare Group
  Careif
  Critical Psychiatry Network
  Genomics England
  Health Services Research Unit, Department of Public Health, University of Oxford
  Institute of Psychiatry
  Joseph Rowntree Foundation
  MRC Clinical Trials Unit
  National Institute for Health Research
  National Primary Care Research & Development Centre

Timeline

Key events during the development of the guidance:

Date Update
09 January 2025 Invitation to participate
11 November 2024 (14:00) Scoping workshop
16 September 2024 - 14 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6431
16 September 2024 In progress. Scoping commencing
07 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual